CRYOcheck? Factor VIII Deficient Plasma with VWF is intended for use as a deficient substrate in clot-based factor VIII (FVIII) activity assays using the one-stage activated partial thromboplastin time (APTT) method.

It is manufactured from platelet-poor plasma, which is immunodepleted and assayed at less than 1% FVIII activity by functional and antigenic methods. Purified VWF is then reintroduced, resulting in a deficient plasma with normal levels of VWF and FVIII antigen levels of less than 1%. The importance of FVIII antigen levels in the performance of FVIII deficient substrates was demonstrated in a study presented at ISTH 2021^*. VWF activity and antigen levels are available for every lot. The plasma is buffered and frozen, resulting in a top quality product that is consistent vial to vial.

CE Marked and Health Canada authorized. Included on the Australian Register of Therapeutic Goods (ARTG). FDA clearance pending: not for sale in the U.S.

• Frozen format eliminates reconstitution errors
• Factor VIII antigen level less than 1%
• Contains normal levels of VWF activity and antigen
• 24-hour stability once thawed if refrigerated at 2 °C to 8 °C in the original capped vial
• Source plasmas are screened negative for all FDA-required tests

^*?A. Wood, N. Kesavan, A. Sadeghi-Khomami, K. Black, M. Boylan, R. Ni, J. Della Maestra, P. Erb, D. Foulon, H. Hoogendoorn; ISTH 2021; The Impact of Inactive FVIII Antigen in Factor VIII Deficient Plasma on the Measurement of FVIII Inhibitors.